Clinical features of multiple myeloma invasion of the central nervous system in Chinese patients.
BACKGROUND
Although neurologic manifestations often complicate the course of patients with multiple myeloma, direct central nervous system invasion is rare. This study explored the neurologic symptoms, signs, clinical features, therapy and prognosis of Chinese patients with central nervous system myeloma invasion.


METHODS
The diagnosis, therapy and prognosis were analyzed retrospectively in 11 Chinese multiple myeloma patients with central nervous system infiltration from a total of 625 patients who have been treated at Changzheng Hospital (Shanghai, China) between January 1993 and May 2009. Survival curve was constructed with the use of Kaplan-Meier estimates.


RESULTS
There were 11 patients with central nervous system involvement from 625 multiple myeloma patients. The occurrence rate was 1.8%. Ten of the 11 patients had other extramedullary diseases. Symptoms included cerebral symptoms, cranial nerve palsies, and spinal cord or spinal nerve roots symptoms. Cerebrospinal fluid was abnormal in 7 patients, usually exhibiting pleocytosis and elevated protein content, plus positive cytologic findings. Specific magnetic resonance imaging findings suggestive of central nervous system invasion were found in 9 patients. After a median follow-up of 19 months, 3 patients were alive. The median overall survival for all patients was 23 months, while the median overall survival for patients after central nervous system invasion was merely 6 months.


CONCLUSIONS
It is exceedingly rare for there to be central nervous system infiltration in multiple myeloma patients. When it occurs, the prognosis is extremely poor despite the use of aggressive local and systemic treatment including stem cell transplantation.
Qu
Xiao-yan
XY
Department of Hematology, Changzheng Hospital, Second Hospital Affiliated to the Second Military Medical University, Shanghai 200003, China.
Fu
Wei-jun
WJ
Xi
Hao
H
Zhou
Fan
F
Wei
Wei
W
Hou
Jian
J
D000328:Adult; D000368:Aged; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002490:Central Nervous System / Q000187:drug effects / Q000473:pathology*; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D013792:Thalidomide / Q000627:therapeutic use
D013792:Thalidomide; D003907:Dexamethasone; D008727:Methotrexate